Moreover, while3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) has been theprimary target for dyslipidemia therapy for many years, newer medications such asproprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors,cholesteryl ester transfer protein (CETP) inhibitors and apolipoproteinC3 (APOC3) inhibitors have emerged as novel targets forcholesterol-lowering drug development [18, 19, 20, 21]. Here, CETP is linked to metabolic syndrome.